{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.13","value":"48.6"},{"groupId":"OG001","spread":"20.75","value":"52.0"},{"groupId":"OG002","spread":"23.12","value":"52.6"},{"groupId":"OG003","spread":"19.66","value":"49.8"}]}],"title":"FACT Fatigue Concerns"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.08","value":"60.6"},{"groupId":"OG001","spread":"16.64","value":"62.2"},{"groupId":"OG002","spread":"16.27","value":"61.3"},{"groupId":"OG003","spread":"13.39","value":"59.4"}]}],"title":"FACT Nonfatigue Concerns"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.58","value":"52.8"},{"groupId":"OG001","spread":"18.08","value":"55.6"},{"groupId":"OG002","spread":"19.85","value":"55.6"},{"groupId":"OG003","spread":"16.24","value":"53.1"}]}],"title":"FACT Total Anemia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"}],"units":"Participants"}],"description":"To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. FACT-AN consist of Fatigue concerns subscale and non-fatigue concerns subscale. FACT Total Anemia score was calculated by adding the two subscales scores and transformed into 0-100 scale. FACT Total Anemia, Fatigue concerns scale and Non-Fatigue concerns scale are all ranges: 0 (Worst QOL) to 100 (Best QOL). Average scores across all time points for each subscale and total scale were calculated.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)","id":"OG000","title":"Epoetin Alfa - 40k Weekly"},{"description":"Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG001","title":"Epoetin Alfa - 80k Every 3 Weeks"},{"description":"Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG002","title":"Epoetin Alfa - 120k Every 3 Weeks"},{"description":"Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG003","title":"Darbepoetin Alfa - 500 mcg Every 3 Weeks"}],"paramType":"MEAN","populationDescription":"All patients that were evaluable per protocol with QOL data.","reportingStatus":"POSTED","timeFrame":"Weeks 4, 7, 10, 13 and 16","title":"Quality of Life as Measured by Functional Assessment of Cancer Therapy Scales for Anemia (FACT-AN) Over All Follow-up Evaluations","type":"SECONDARY","unitOfMeasure":"units on a scale"}